Esperion’s Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia
Go back to Esperion’s Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia| ESPERION THERAP (NASDAQ: ESPR) | Delayed: 3.15 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.15 | 52 Week High | $30.41 | |||
| Open | $3.15 | 52 Week Low | $9.40 | |||
| Day High | $3.16 | P/E | N/A | |||
| Day Low | $3.15 | EPS | $-21.87 | |||
| Volume | 8,816,068 | |||||
